San Francisco startup Construction Therapeutics can be focusing on an oral, when-everyday GLP-1 drug named GSBR-1290—the drug surpassed Wall Avenue’s expectations in June when a mid-phase study showed regular weight loss of all over six% and it plans to begin One more mid-phase demo